高强度聚焦超声联合健择治疗晚期胰腺癌的临床研究  

High intensity focused ultrasound therapy in combination with gemcitabine for advanced pancreatic carcinoma

作　　者：曾庆东[1] 吕丽红[2] 张秀国[1] 吕斌[1] 高学军[3] 公伟[1] 李占元[1] 

机构地区：[1]山东大学齐鲁医院普通外科,济南市250012 [2]山东大学齐鲁医院医学院手术学教研室,济南市250012 [3]博兴县人民医院外科

出　　处：《中华肝胆外科杂志》2006年第11期748-750,共3页Chinese Journal of Hepatobiliary Surgery

摘　　要：目的探讨高强度聚焦超声(HIFU)联合健择治疗晚期胰腺癌的有效性。方法将46例不能切除的晚期胰腺癌无黄疸病人随机分为:HIFU联合健择组24例,单用健择组22例。全部病例随访2～18个月。Kaplan-Meier法进行生存分析,计算6个月、12个月生存率和中位生存期;采用LogRank法进行组间比较。两组治疗后的疼痛缓解率采用x2检验。结果HIFU联合健择组的24例病人中位生存时间为10．56个月,6个月和12个月的生存率分别是75．0％和30．9％;而单用健择组的22例病人中位生存时间为6．71个月,6个月和12个月的生存率分别是36．4％和13．0％。两组比较,HIFU联合健择组优于单用健择组,差异有显著性(P<0．01)。HIFU联合健择组24例病人的疼痛缓解率(疼痛强度降低或消失,止痛剂减少或停止应用)87．5％;而单用健择组22例病人的缓解率为36．4％。两组比较,HIFU联合健择组明显优于单用健择组(P<0．01)。结论HIFU联合健择组治疗晚期胰腺癌的疗效明显优于单用健择组,因此本方法有望成为治疗晚期胰腺癌的一种有效手段。Objective To study high intensity focused ultrasound therapy （HIFUT） in combination with gemcitabine for treatment of advanced pancreatic carcinoma （APC）. Methods A total of 46 patients were randomized into 2 groups. The patients in group A （n=24） received HIFUT in combination with gemcitabine and those in group B （n=22） were given gemcitabine alone. The follow-up time was 2-- 18 months in both groups. The median survival time, 6-month and 12-month survival rates were calculated by Kaplan-Meier method and LogRank test. The pain remission rate of the 2 groups was compared by Ze test. Results The median survival time, 6-month and 12-month survival rates were significantly higher in group A than in group B （10. 56 months vs. 6.71 months, 75.0% vs. 36.4%, 30. 9% vs. 13.0%, P〈0. 01）. Meanwhile, the pain remission rate was markedly higher in group A than in group B （87.5% vs. 36.4%, P〈0. 01）. Conclusions HIFUT in combination with gemcitabine is better than gemcitabine alone. The former may become of the most effective treat ments for APC.

关 键 词：胰腺肿瘤 高强度聚焦超声 健择 

分 类 号：R735.9[医药卫生—肿瘤]